<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386007</url>
  </required_header>
  <id_info>
    <org_study_id>DW 3101_201</org_study_id>
    <nct_id>NCT02386007</nct_id>
  </id_info>
  <brief_title>Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients</brief_title>
  <official_title>A Double-blind, Multicenter, Randomized Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Korean Patients With Gastric Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find optimum dosage of DW-3101 by evaluating efficacy and
      safety of each dosage group in Korean patients with acute and chronic gastric inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of gastric erosion score</measure>
    <time_frame>14dayÂ±3</time_frame>
    <description>The erosion score is evaluated by gastroscopy. Erosion score The number of erosion
0
1~2
3~5
More than 6 If patient's erosion score is decreased by 50% compared with erosion score before clinical dosing, we count it as effectiveness.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute and Chronic Gastric Inflammation Patients</condition>
  <arm_group>
    <arm_group_label>DW-3101_150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DW-3101_300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DW-3101_600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>a tablet same as experimental agents in formation and shape</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-3101_150mg</intervention_name>
    <arm_group_label>DW-3101_150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-3101_300mg</intervention_name>
    <arm_group_label>DW-3101_300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-3101_600mg</intervention_name>
    <arm_group_label>DW-3101_600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>a tablet same as experimental agents in formation and shape</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males/females aged 20~75 years

          -  Patients detected over 1 erosion who diagnosed as acute or chronic gastric
             inflammation by gastrscopy in 7days before administration of experimental agents

          -  Subjects who voluntarily agree to participate in this clinical test with written
             consent

        Exclusion Criteria:

          -  Patients impossible gastroscopy

          -  In case accompanied with gastric ulcer(scar excepted) or reflux esophagitis

          -  Patients who had stomach or esophagus surgery to inhibit gastric acid secretion
             (tresis or appendicectomy surgery excluded)

          -  Patients with malignant tumor on digestive organ

          -  Patients with blood clot(cerebral thrombosis, myocardial infarction, septic
             thrombophlebitis) and who have antithrombotic agents (eg. warfarin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

